Last $60.79 USD
Change Today -0.21 / -0.34%
Volume 543.0K
ABMD On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 5:20 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

abiomed inc (ABMD) Snapshot

Open
$60.53
Previous Close
$61.00
Day High
$61.53
Day Low
$60.36
52 Week High
02/26/15 - $61.94
52 Week Low
05/8/14 - $20.29
Market Cap
2.5B
Average Volume 10 Days
513.4K
EPS TTM
$0.49
Shares Outstanding
41.1M
EX-Date
--
P/E TM
124.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for ABIOMED INC (ABMD)

Related News

No related news articles were found.

abiomed inc (ABMD) Related Businessweek News

No Related Businessweek News Found

abiomed inc (ABMD) Details

ABIOMED, Inc. provides medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients. Its products consist of Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP, a micro heart pump; and Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite. The company also manufactures and sells the Impella RP, a percutaneous catheter-based axial flow pump; and AB5000 circulatory support system and the BVS 5000 biventricular support system for temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. In addition, it offers Symphony, a synchronized minimally invasive implantable cardiac assist device designed to treat chronic patients with moderate heart failure by improving patient hemodynamics; and AbioCor program. The company sells its products through direct sales and clinical support personnel in the United States, Canada, Germany, France, the United Kingdom, and internationally. ABIOMED, Inc. was founded in 1981 and is headquartered in Danvers, Massachusetts.

511 Employees
Last Reported Date: 05/28/14
Founded in 1981

abiomed inc (ABMD) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $519.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $315.9K
Chief Operating Officer
Total Annual Compensation: $341.8K
Vice President and General Manager of Global ...
Total Annual Compensation: $297.0K
Senior Vice President of Global Product Opera...
Total Annual Compensation: $284.6K
Compensation as of Fiscal Year 2014.

abiomed inc (ABMD) Key Developments

ABIOMED, Inc. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 01:00 PM

ABIOMED, Inc. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 01:00 PM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Michael R. Minogue, Chairman, Chief Executive Officer, President, Member of Special Stock Option Committee and Member of Executive Committee.

Abiomed Inc Receives FDA HDE Approval for the Impella RP

Abiomed Inc. announced that the Impella RP® (Right Percutaneous) System has received U.S. Food and Drug Administration (FDA) approval under a Humanitarian Device Exemption (HDE). This innovative medical device is the first percutaneous single access heart pump designed for right heart support to receive FDA approval. Abiomed completed the HDE submission for the Impella RP in September 2014 following the completion of the RECOVER RIGHT study. Delivered through a catheter requiring only a small hole in the leg, the Impella RP is FDA indicated for providing circulatory assistance for up to 14 days in pediatric or adult patients who develop acute right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, or open-heart surgery. These patients lack blood flow from the right side of their hearts. The Impella RP is designed to provide the flow and pressure needed to compensate for right heart failure. The device does not require a surgical procedure for insertion, and it provides up to four liters per minute of hemodynamic support. There will be a controlled launch of the Impella RP in the U.S. after each site completes in-house training at Abiomed. This rigorous training will incorporate members of the heart team, including the interventional cardiologist, cardiac surgeon, heart failure cardiologist and lead nurse.

ABIOMED, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014; Provides Earnings Guidance for Fiscal Year 2015 and Revenue Guidance for the Fiscal Year 2016

ABIOMED, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, the company reported net income of $12,684,000 or $0.30 per diluted share compared to $4,393,000 or $0.11 per diluted share for the same period last year. Income before provision for income taxes was $13,701,000 compared to $4,651,000 for the same period last year. Income from operations was $13,663,000 compared to $4,594,000 for the same period last year. Total revenue was $62,005,000 compared to $46,195,000 for the same period last year. For the nine months, the company reported net income of $14,814,000 or $0.35 per diluted share compared to $3,729,000 or $0.09 per diluted share for the same period last year. Income before provision for income taxes was $16,393,000 compared to $4,768,000 for the same period last year. Income from operations was $16,303,000 compared to $4,685,000 for the same period last year. Total revenue was $162,754,000 compared to $133,210,000 for the same period last year. The company provided earnings guidance for fiscal year 2015 and revenue guidance for the fiscal year 2016. For the period, the company is increasing its guidance for total revenue to be in the range of $223 million to $226 million, an increase of 21% to 23% from the prior year. This new range compares to the previous range of $209 million to $212 million, which represented an increase of 14% to 15% from the prior year. The company is also increasing its fiscal year 2015 guidance for GAAP operating margin to be in the range of 9% to 11% from the previous range of 1% to 4%. The company is estimating fiscal year 2016 revenue in the range of $260 million to $270 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABMD:US $60.79 USD -0.21

ABMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AtriCure Inc $17.68 USD -0.25
Hansen Medical Inc $0.78 USD -0.1158
LeMaitre Vascular Inc $7.62 USD -0.27
Spectranetics Corp/The $33.81 USD +0.37
Thoratec Corp $40.72 USD +0.20
View Industry Companies
 

Industry Analysis

ABMD

Industry Average

Valuation ABMD Industry Range
Price/Earnings 100.0x
Price/Sales 11.7x
Price/Book 12.7x
Price/Cash Flow 136.0x
TEV/Sales 11.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABIOMED INC, please visit www.abiomed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.